Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 623 of 5804
-
Could a melanoma drug combo tame rare BRAF cancers?
Disease control Recruiting nowThis clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for th…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cocktail aims to tackle stomach cancer when first treatment fails
Disease control OngoingThis is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a party drug ease PTSD? new trial tests methylone
Symptom relief CompletedThis study is evaluating the safety, tolerability, and efficacy of methylone in adults with PTSD. The study will be conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1), double-blind, placebo-controlled and w…
Phase: PHASE1, PHASE2 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Brain zaps for depression: scientists hunt for clues in electrical signals
Disease control Recruiting nowOf the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depr…
Phase: NA • Sponsor: Helen Mayberg, MD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Bladder cancer patients may skip surgery with new drug combo
Disease control OngoingIntravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer (NMIBC) is a well-established treatment for preventing or delaying tumor recurrence after tumor resection. For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical…
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo shows promise against hodgkin lymphoma
Disease control CompletedThis study will be held in the clinical oncology department, Helwan University, and Police Hospital, aiming to compare the efficacy and safety of anti-CD30 (BV) + Doxorubicin, Vinblastine, and Dacarbazine (AVD) versus the standard of care Doxorubicin, Bleomycin, Vinblastine, and …
Phase: NA • Sponsor: Helwan University • Aim: Disease control
Last updated Jun 26, 2026 17:09 UTC
-
New trial combines drugs with surgery or radiation to fight advanced prostate cancer
Disease control Recruiting nowItalian multicenter study, will enroll \~566 pts with oligometastatic hormone sensitive prostate cancer who are candidates to receive treatment with apalutamide. After 6 months from the start of treatment, patients will be randomized to receive local treatment based on the inves…
Phase: NA • Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Disease control
Last updated Jun 26, 2026 13:15 UTC
-
Arterial chemo combo shows promise in stomach cancer trial
Disease control Recruiting nowSOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadj…
Phase: PHASE3 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New heart zapping device shows promise for stubborn AFib
Disease control CompletedThe objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New oil therapy could slash Life-Threatening events in kids with rare metabolic disease
Disease control OngoingThe main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a cancer therapy tame severe lupus? early trial launches
Disease control OngoingThe study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New dosing strategy aims to make Alzheimer's drug safer and more effective
Disease control OngoingThis study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA. Approximately 375 additiona…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug ABC008 shows promise in slowing rare muscle disease
Disease control CompletedA Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Phase: PHASE2, PHASE3 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a common diabetes drug curb weight gain in people with intellectual disabilities?
Disease control Recruiting nowPeople with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD.…
Phase: PHASE4 • Sponsor: Centre for Addiction and Mental Health • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New immunotherapy shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThe main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic c…
Phase: PHASE3 • Sponsor: Taizhou Hanzhong biomedical co. LTD • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Molecular blueprint may unlock personalized liver cancer therapy
Knowledge-focused Recruiting nowHepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious. Within the same tumour, different parts of the HCC can belong to separate molecular sub-groups…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New mRNA inhalation therapy offers hope for Hard-to-Treat cystic fibrosis
Disease control OngoingThe purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Phase: PHASE1, PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo aims to boost transplant success in Hodgkin's lymphoma
Disease control Recruiting nowThe phase I part (safety assessment of the combination treatment) is aimed at determining the MTD of atezolizumab when combined with BEGEV schedule. 6-18 patients enrolled in this part will be treated with atezolizumab in combination with BEGEV regimen every 3 weeks for 4 cycles…
Phase: PHASE1, PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Blood test could detect hidden pancreatic tumors
Diagnosis Recruiting nowThis prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Could a vaccine fight Alzheimer's? new trial begins
⭐️ VACCINE ⭐️ OngoingPhase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Phase: PHASE1 • Sponsor: Institute for Molecular Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC